UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026**

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO**

Commission file number: 001-37401

Community Healthcare Trust Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Maryland	**46-5212033**
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

3326 Aspen Grove Drive
Suite 150
Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)

(615) 771-3052
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.01 par value per share	CHCT	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	Accelerated filer	Emerging-growth company	Non-accelerated filer	Smaller reporting company
☐	☒	☐	☐	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The Registrant had 28,739,383 shares of Common Stock, $0.01 par value per share, outstanding as of October 27, 2026.

COMMUNITY HEALTHCARE TRUST INCORPORATED
FORM 10-Q
SEPTEMBER 30, 2026

TABLE OF CONTENTS

		Page
PART I.—FINANCIAL INFORMATION		
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Income (Loss)	5
	Condensed Consolidated Statements of Stockholders' Equity	6
	Condensed Consolidated Statements of Cash Flows	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	36
Item 4.	Controls and Procedures	36
PART II.—OTHER INFORMATION		37
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	37
Item 4.	Mine Safety Disclosures	37
Item 5.	Other Information	37
Item 6.	Exhibits	38
SIGNATURES		39

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars and shares in thousands, except per share amounts)

	(Unaudited) September 30, 2026	December 31, 2025
ASSETS		
Real estate properties		
Land and land improvements	$ 160,321	$ 154,673
Buildings, improvements, and lease intangibles	1,058,175	1,047,743
Personal property	816	813
Total real estate properties	1,219,312	1,203,229
Less accumulated depreciation	(308,944)	(280,316)
Total real estate properties, net	910,368	922,913
Cash and cash equivalents	1,350	3,340
Assets held for sale, net	22,588	5,265
Other assets, net	66,105	59,239
Total assets	$ 1,000,411	$ 990,757
LIABILITIES AND STOCKHOLDERS' EQUITY		
Liabilities		
Debt, net	$ 558,382	$ 532,199
Accounts payable and accrued liabilities	15,281	14,925
Other liabilities, net	13,308	14,246
Total liabilities	586,971	561,370
Commitments and contingencies		
Stockholders' Equity		
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding	—	—
Common stock, $0.01 par value; 450,000 shares authorized; 28,739 and 28,471 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	287	285
Additional paid-in capital	724,107	717,450
Cumulative net income	98,757	90,777
Accumulated other comprehensive income	13,028	6,691
Cumulative dividends	(422,739)	(385,816)
Total stockholders’ equity	413,440	429,387
Total liabilities and stockholders' equity	$ 1,000,411	$ 990,757

See accompanying notes to the condensed consolidated financial statements.

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited; Dollars and shares in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
REVENUES				
Rental income	$ 32,193	$ 30,814	$ 94,433	$ 90,672
Other operating interest	250	272	758	(423)
	32,443	31,086	95,191	90,249
EXPENSES				
Property operating	5,975	5,930	18,209	17,610
General and administrative [(1)]	4,191	4,658	14,189	20,317
Depreciation and amortization	10,668	10,902	32,063	32,724
	20,834	21,490	64,461	70,651
OTHER (EXPENSE) INCOME				
Losses on sale and impairment of real estate assets, net of gains on sale	(1,039)	(888)	(1,039)	(248)
Interest expense	(7,515)	(7,075)	(21,742)	(20,019)
Credit loss reserve	—	—	—	(8,672)
Deferred income tax benefit	—	—	12	—
Interest and other income, net	13	7	19	15
	(8,541)	(7,956)	(22,750)	(28,924)
NET INCOME (LOSS)	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
Net income (loss) per common share - Basic & Diluted	$ 0.09	$ 0.03	$ 0.22	$ (0.43)
Weighted Average Common Shares Outstanding- Basic & Diluted	27,070	26,934	27,026	26,824

(1) General and administrative expenses for the three and nine months ended September 30, 2026 included stock-based compensation expense totaling approximately $1.9 million and $7.4 million, respectively. General and administrative expenses for the three and nine months ended September 30, 2025 included stock-based compensation expense totaling approximately $2.5 million and $12.3 million, respectively. General and administrative expenses for the nine months ended September 30, 2025 included severance and transition-related expenses totaling $1.3 million and accelerated non-cash stock-based compensation amortization of $4.6 million related to the termination of a former executive officer. See Note 9 – Stock Incentive Plan.

See accompanying notes to the condensed consolidated financial statements.

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited; Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
NET INCOME (LOSS)	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
Other comprehensive income (loss):				
Increase (decrease) in fair value of cash flow hedges	4,931	308	9,425	(4,568)
Reclassification for amounts recognized as interest expense	(950)	(1,861)	(3,088)	(5,495)
Total other comprehensive income (loss)	3,981	(1,553)	6,337	(10,063)
COMPREHENSIVE INCOME (LOSS)	$ 7,049	$ 87	$ 14,317	$ (19,389)

See accompanying notes to the condensed consolidated financial statements.

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026
(Unaudited; Dollars and shares in thousands, except per share amounts)

	Preferred Stock		Common Stock		Additional Paid in Capital	Cumulative Net Income	Accumulated Other Comprehensive Income	Cumulative Dividends	Total Stockholders' Equity
	Shares	Amount	Shares	Amount					
Balance at June 30, 2026	—	$ —	28,655	$ 287	$ 722,454	$ 95,689	$ 9,047	$ (413,235)	$ 414,242
Issuance costs on stock-based compensation	—	—	—	—	(53)	—	—	—	(53)
Stock-based compensation, net of forfeitures	—	—	96	—	1,903	—	—	—	1,903
Shares withheld on vesting of stock-based compensation	—	—	(12)	—	(197)	—	—	—	(197)
Increase in fair value of cash flow hedges	—	—	—	—	—	—	4,931	—	4,931
Reclassification for amounts recognized as interest expense	—	—	—	—	—	—	(950)	—	(950)
Net income	—	—	—	—	—	3,068	—	—	3,068
Dividends to common stockholders ($0.3300 per share)	—	—	—	—	—	—	—	(9,504)	(9,504)
Balance at September 30, 2026	—	$ —	28,739	$ 287	$ 724,107	$ 98,757	$ 13,028	$ (422,739)	$ 413,440
Balance at December 31, 2025	—	$ —	28,471	$ 285	$ 717,450	$ 90,777	$ 6,691	$ (385,816)	$ 429,387
Issuance costs on stock-based compensation	—	—	—	—	(138)	—	—	—	(138)
Stock-based compensation, net of forfeitures	—	—	303	2	7,390	—	—	—	7,392
Shares withheld on vesting of stock-based compensation	—	—	(35)	—	(595)	—	—	—	(595)
Increase in fair value of cash flow hedges	—	—	—	—	—	—	9,425	—	9,425
Reclassification for amounts recognized as interest expense	—	—	—	—	—	—	(3,088)	—	(3,088)
Net income	—	—	—	—	—	7,980	—	—	7,980
Dividends to common stockholders ($1.2875 per share)	—	—	—	—	—	—	—	(36,923)	(36,923)
Balance at September 30, 2026	—	$ —	28,739	$ 287	$ 724,107	$ 98,757	$ 13,028	$ (422,739)	$ 413,440

See accompanying notes to the condensed consolidated financial statements.

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
(Unaudited; Dollars and shares in thousands, except per share amounts)

	Preferred Stock		Common Stock		Additional Paid in Capital	Cumulative Net Income	Accumulated Other Comprehensive Income	Cumulative Dividends	Total Stockholders' Equity
	Shares	Amount	Shares	Amount					
Balance at June 30, 2025	—	$ —	28,368	$ 284	$ 712,498	$ 74,709	$ 9,121	$ (358,792)	$ 437,820
Issuance costs on stock-based compensation	—	—	—	—	(14)	—	—	—	(14)
Stock-based compensation, net of forfeitures	—	—	108	1	2,464	—	—	—	2,465
Shares withheld on vesting of stock-based compensation	—	—	(5)	—	(58)	—	—	—	(58)
Increase in fair value of cash flow hedges	—	—	—	—	—	—	308	—	308
Reclassification for amounts recognized as interest expense	—	—	—	—	—	—	(1,861)	—	(1,861)
Net income	—	—	—	—	—	1,640	—	—	1,640
Dividends to common stockholders ($0.4725 per share)	—	—	—	—	—	—	—	(13,477)	(13,477)
Balance at September 30, 2025	—	$ —	28,471	$ 285	$ 714,890	$ 76,349	$ 7,568	$ (372,269)	$ 426,823
Balance at December 31, 2024	—	$ —	28,242	$ 282	$ 704,524	$ 85,675	$ 17,631	$ (332,147)	$ 475,965
Issuance costs on stock-based compensation	—	—	—	—	(136)	—	—	—	(136)
Stock-based compensation, net of forfeitures	—	—	336	3	12,294	—	—	—	12,297
Shares withheld on vesting of stock-based compensation	—	—	(107)	—	(1,792)	—	—	—	(1,792)
Decrease in fair value of cash flow hedges	—	—	—	—	—	—	(4,568)	—	(4,568)
Reclassification for amounts recognized as interest expense	—	—	—	—	—	—	(5,495)	—	(5,495)
Net loss	—	—	—	—	—	(9,326)	—	—	(9,326)
Dividends to common stockholders ($1.4100 per share)	—	—	—	—	—	—	—	(40,122)	(40,122)
Balance at September 30, 2025	—	$ —	28,471	$ 285	$ 714,890	$ 76,349	$ 7,568	$ (372,269)	$ 426,823

See accompanying notes to the condensed consolidated financial statements.

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in thousands)

	Nine Months Ended September 30,	
	2026	**2025**
OPERATING ACTIVITIES		
Net income (loss)	$ 7,980	$ (9,326)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization	32,063	32,724
Other amortization	872	905
Stock-based compensation	7,392	7,706
Accelerated amortization of stock-based compensation	—	4,591
Straight-line rent receivable	(2,197)	(2,736)
Losses on sale and impairment of real estate assets, net of gains on sale	1,039	248
Credit loss reserve	—	8,672
Changes in operating assets and liabilities:		
Other assets	93	1,215
Accounts payable and accrued liabilities	(718)	(228)
Other liabilities	(1,377)	(2,841)
Net cash provided by operating activities	45,147	40,930
INVESTING ACTIVITIES		
Acquisitions of real estate	(28,514)	(36,074)
Proceeds from sale of real estate	6,355	1,266
Proceeds from the repayment of notes receivable	450	5,095
Capital expenditures on existing real estate properties	(13,878)	(13,987)
Net cash used in investing activities	(35,587)	(43,700)
FINANCING ACTIVITIES		
Net borrowings on revolving credit facility	26,000	44,000
Dividends paid	(36,923)	(40,122)
Taxes paid on behalf of employees and shares withheld upon shares vesting	(595)	(1,792)
Equity issuance costs	(32)	(317)
Net cash (used in) provided by financing activities	(11,550)	1,769
Decrease in cash and cash equivalents	(1,990)	(1,001)
Cash and cash equivalents, beginning of period	3,340	4,384
Cash and cash equivalents, end of period	$ 1,350	$ 3,383
Supplemental Cash Flow Information:		
Interest paid (net of capitalized interest)	$ 20,958	$ 19,232
Invoices accrued for construction, tenant improvement, and other capitalized costs	$ 6,802	$ 8,654
Reclassification between other assets and proceeds from sale of real estate	$ 664	$ —
Reclassification of registration statement costs to equity issuance costs	$ 138	$ 139
Increase (decrease) in fair value of cash flow hedges	$ 9,425	$ (4,568)
Income taxes paid	$ 174	$ 20
Capitalized interest	$ 120	$ 118

See accompanying notes to the condensed consolidated financial statements.

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Overview

Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of September 30, 2026, the Company had gross investments of approximately $1.2 billion in 196 real estate properties (including one property with sales-type leases with a gross investment totaling approximately $8.1 million and two properties classified as assets held for sale with an aggregate net investment totaling approximately $21.7 million). The properties are located in 36 states, totaling approximately 4.5 million square feet in the aggregate, with a weighted average remaining lease term of approximately 7.1 years. Excluding the real estate assets held for sale the properties were approximately 90.1% leased. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2026. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Condensed Consolidated Financial Statements

Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes, including among others, estimates related to impairment assessments, purchase price allocations, allowances for accounts and interest receivables, and valuation of financial instruments. Actual results may materially differ from those estimates.

Segment Reporting

The Company invests in healthcare-related real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers throughout the U.S. The Company operates and manages its business as one reportable operating segment. Operating segments are defined as components of an enterprise where separate financial information is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance. The Company's CODM is the Chief Executive Officer who reviews total consolidated assets and consolidated net income and assesses the performance of the Company's portfolio and makes operating decisions accordingly. There are no significant segment expenses which require disclosure other than the expenses presented on the Condensed Consolidated Statements of Operations.

Cash and Cash Equivalents

Cash and cash equivalents may include short-term investments with original maturities of three months or less when purchased. The carrying amounts approximate fair value due to the short-term maturity of these investments.

Accounting Pronouncements Not Yet Adopted

ASU 2024-03, Disaggregation of Income Statement Expenses, will require entities to provide enhanced disclosures related to certain expense categories included in income statement captions. ASU 2024-03 aims to increase transparency and provide investors with more detailed information about the nature of expenses reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. Entities will be required to disaggregate, in a tabular format, expense captions presented on the face of the income statement, including but not limited to employee compensation, intangible asset amortization, and depreciation and amortization within a footnote to its Consolidated Financial Statements. For any remaining items within each relevant expense caption, entities must provide a qualitative description of the nature of those expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027 though early adoption is permitted. While the adoption is not expected to have a material impact on our financial statements, it is expected to result in incremental disclosures within the footnotes to our Consolidated Financial Statements.

ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, provides clarity on the current interim reporting requirements and the applicability of ASC 270. The new guidance creates a comprehensive list of interim disclosures required under GAAP and incorporates a disclosure principle that requires disclosures at interim periods when an event or change that has a material effect on an entity has occurred since the last annual reporting period. Some examples that may require disclosure under this new principle include changes in (i) accounting principles or estimates, (ii) status of long-term contracts, (iii) capitalization, such as new borrowings or financing modifications, and (iv) reporting entity resulting from business combinations or disposals. The amendments are effective for interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact the adoption of this standard may have on its interim Condensed Consolidated Financial Statements.

NOTE 2. REAL ESTATE INVESTMENTS

As of September 30, 2026, we had gross investments of approximately $1.2 billion in 196 real estate properties (including one property with sales-type leases with a gross investment totaling approximately $8.1 million and two properties classified as assets held for sale with a net real estate investment totaling approximately $21.7 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:

Property Type	# of Properties		Gross Investment (in thousands)
Medical Office Building	92	$	482,113
Inpatient Rehabilitation Hospitals	11		260,819
Acute Inpatient Behavioral	11		173,769
Specialty Centers	35		111,619
Physician Clinics	32		106,436
Surgical Centers and Hospitals	6		47,097
Behavioral Specialty Facilities	7		45,720
Long-term Acute Care Hospitals	2		21,484
Total	**196**	**$**	**1,249,057**

State	# of Properties	Gross Investment (in thousands)
Florida	26	$ 188,240
Texas	15	165,819
Illinois	19	141,423
Ohio	25	116,686
Pennsylvania	15	68,688
All Others	96	568,201
Total	**196**	**$ 1,249,057**

Primary Tenant	# of Properties	Gross Investment (in thousands)
US HealthVest	3	$ 77,964
PAM Health	2	55,035
All Others (less than 4%)	191	1,116,058
Total	**196**	**$ 1,249,057**

NOTE 3. REAL ESTATE LEASES

Lessor Accounting

The Company's properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2046. The Company's leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of certain taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease.

Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of September 30, 2026, are as follows (in thousands):

2026 (three months ending December 31)	$ 28,645
2027	111,165
2028	103,668
2029	92,291
2030	85,895
2031 and thereafter	473,698
	$ 895,362

Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent increased rental income by approximately $0.8 million and $2.2 million for the three and nine months ended September 30, 2026, respectively, and by $0.9 million and $2.7 million for the three and nine months ended September 30, 2025, respectively.

Purchase Option Provisions

Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. The Company had an aggregate gross investment of approximately $38.2 million in 11 real estate properties with purchase options outstanding at September 30, 2026 that had not been exercised.

Sales-type Leases

The Company has one property with two sales-type leases with a net investment totaling approximately $7.7 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under these leases for the years ending December 31, as of September 30, 2026, are as follows (in thousands):

2026 (three months ending December 31)	$ 219
2027	888
2028	909
2029	932
2030	954
2031 and thereafter	8,664
Total undiscounted lease receivable	12,566
Discount	(4,858)
Lease receivable	$ 7,708

The Company recognized interest income of approximately $0.2 million during each of the three months ended September 30, 2026 and 2025, and recognized approximately $0.5 million and $0.4 million, respectively, for the nine months ended September 30, 2026 and 2025, which is included in other operating interest on the Company's Condensed Consolidated Statements of Operations.

Lessee Accounting

At September 30, 2026, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as finance leases with expiration dates, including renewal options, through 2109. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):

	Operating	Financing
2026 (three months ending December 31)	$ 11	$ 39
2027	45	154
2028	46	154
2029	47	154
2030	48	154
2031 and thereafter	1,007	6,493
Total undiscounted lease payments	1,204	7,148
Discount	(465)	(3,914)
Lease liabilities	$ 739	$ 3,234

The following table discloses other information regarding the ground leases.

	Three Months Ended September 30,	
	2026	2025
Operating leases:		
Weighted-average remaining lease term in years (including renewal options)	31.8	33.0
Weighted-average discount rate	4.1 %	4.0 %
Financing leases:		
Weighted-average remaining lease term in years (including renewal options)	37.2	38.1
Weighted-average discount rate	4.3 %	4.3 %

NOTE 4. REAL ESTATE ACQUISITION, DISPOSITION, AND ASSETS HELD FOR SALE

Acquisition

During the first quarter of 2026, the Company acquired one real estate property as detailed in the table below. The property is 100% leased to a tenant with a lease expiration in 2044. Amounts reflected in revenues and net income for the property for the nine months ended September 30, 2026 were approximately $1.9 million and $1.6 million, respectively, and transaction costs totaling approximately $19,000 were capitalized relating to the property acquisition.

The following table summarizes our property acquisitions for the nine months ended September 30, 2026:

Location	Property Type [1]	Number of Properties	Date Acquired	Purchase Price	Cash Consideration	Real Estate	Other [2]	Square Footage
				(000's)	(000's)	(000's)	(000's)	
Pinellas Park, FL	IRF	1	2/19/2026	$ 28,500	$ 28,514	$ 28,519	$ (5)	37,151
				$ 28,500	$ 28,514	$ 28,519	$ (5)	37,151

[1] IRF - Inpatient Rehabilitation Facility

[2] May include items including, but not limited to, other assets, liabilities assumed, and security deposits.

The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the nine months ended September 30, 2026:

	Estimated Fair Value	Weighted Average Useful Life
	(In thousands)	*(In years)*
Land and land improvements	$ 7,877	22.0
Buildings and building improvements	20,642	50.0
Accounts payable, accrued liabilities and other liabilities acquired	(5)	
Total cash consideration	$ 28,514	

Asset Dispositions and Assets Held for Sale

As part of the Company's capital recycling program, the Company has sold the following properties during 2026:

- During the third quarter of 2026, the Company sold a property, received net proceeds of approximately $0.1 million, and recorded a $0.7 million loss on sale.
- During the second quarter of 2026, the Company sold a property, received net proceeds of approximately $0.4 million, and recorded a $46,000 gain on sale.
- During the first quarter of 2026, the Company sold a property, received net proceeds of approximately $5.2 million, and recorded a $46,000 loss on sale. The property was classified as held for sale at December 31, 2025. During the first quarter of 2026, the Company also received net cash proceeds of approximately $0.7 million for a property disposed of during the fourth quarter of 2025.

The Company also had two properties classified as assets held for sale at September 30, 2026 and one property held for sale at December 31, 2025. During the third quarter of 2026, the Company recognized an impairment of approximately $0.4 million related to a property held for sale at September 30, 2026, based on the estimated fair value less costs to sell.

The table below reflects the assets classified as held for sale for each of those periods.

(Dollars in thousands)	September 30, 2026	December 31, 2025
Balance Sheet data:		
Land	$ 3,213	$ 1,047
Building, improvements, and lease intangibles	21,123	6,604
	24,336	7,651
Accumulated depreciation	(2,660)	(2,386)
Real estate assets held for sale, net	$ 21,676	$ 5,265
Other assets, net	$ 912	$ —
Assets held for sale, net	$ 22,588	$ 5,265

NOTE 5. DEBT, NET

The table below details the Company's debt as of September 30, 2026 and December 31, 2025.

	Balance as of		
(Dollars in thousands)	September 30, 2026	December 31, 2025	Maturity Dates
Credit Facility:			
Revolving Credit Facility	$ 284,000	$ 258,000	10/2029
A-4 Term Loan, net	124,834	124,749	3/2028
A-5 Term Loan, net	149,548	149,450	3/2030
	$ 558,382	$ 532,199	

Credit Facility

The Company's third amended and restated credit agreement, as amended on October 16, 2024 (the "Credit Facility") is by and among Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent. The Credit Facility provides for a $400.0 million revolving credit facility (the "Revolving Credit Facility") and $275.0 million in term loans (the "Term Loans"). The Revolving Credit Facility matures on October 16, 2029. The Term Loans include a term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and a term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan"), which matures on March 14, 2030. Loans under the Credit Facility are interest only with principal amounts due as of each facility's applicable maturity date. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility.

Amounts outstanding under the Revolving Credit Facility bear interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.15% to 1.75%, plus a simple SOFR adjustment equal to 0.10% per annum, or (ii) a base rate plus 0.15% to 0.75% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. At September 30, 2026, the Company had $284.0 million outstanding under the Revolving Credit Facility with a borrowing capacity remaining of $116.0 million and a floating rate of approximately 5.6%.

Amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.65% to 2.30%, plus a simple SOFR adjustment equal to 0.10% per annum, or (ii) a base rate plus 0.65% to 1.30%, in each case, depending upon the Company’s leverage ratio.

The Company has entered into interest rate swaps to fix certain interest rates on the Credit Facility. At September 30, 2026, the Company had fixed the $275.0 million outstanding under the Term Loans, which had an aggregate fixed weighted average interest rate under the swaps of approximately 4.7%. On March 29, 2026, the swaps that had previously fixed $75.0 million of the Revolving Credit Facility matured. The fixed rate of those matured swaps was 3.8%. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps.

The Company's ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2026.

NOTE 6. DERIVATIVE FINANCIAL INSTRUMENTS

Risk Management Objective of Using Derivatives

The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company's operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations.

Cash Flow Hedges of Interest Rate Risk

The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

As of September 30, 2026, the Company had twelve outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $275.0 million, which mature between 2028 and 2030. Three previously outstanding interest rate swaps for notional amounts totaling $75.0 million matured on March 29, 2026. See Note 5 – Debt, net.

Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025.

	Asset Derivatives Fair Value at			Liability Derivatives Fair Value at		
(Dollars in thousands)	September 30, 2026	December 31, 2025	Balance Sheet Classification	September 30, 2026	December 31, 2025	Balance Sheet Classification
Interest rate swaps	$ 13,028	$ 6,691	Other assets, net	$ —	$ —	Other liabilities, net

The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings.

Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company's Credit Facility. During the next twelve months, the Company estimates that an additional $5.7 million will be reclassified from AOCI as a decrease to interest expense on the Term Loans.

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income

The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and nine months ended September 30, 2026 and 2025.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(Dollars in thousands)	2026	2025	2026	2025
Amount of unrealized gain (loss) recognized in OCI on derivative	$ 4,931	$ 308	$ 9,425	$ (4,568)
Amount of gain reclassified from AOCI into interest expense	$ (950)	$ (1,861)	$ (3,088)	$ (5,495)
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded	$ 7,515	$ 7,075	$ 21,742	$ 20,019

Tabular Disclosures of Offsetting Derivatives

The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of September 30, 2026 and December 31, 2025. As of September 30, 2026 and December 31, 2025 the Company did not have any derivatives in a liability position, therefore we do not present offsetting of derivative liabilities to be reconciled to the tabular disclosure of fair value.

Offsetting of Derivative Assets (as of September 30, 2026)

				Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets		
(In thousands)	Gross Amounts of Recognized Assets	Gross Amounts Offset in the Condensed Consolidated Balance Sheet	Net Amounts of Assets in the Condensed Consolidated Balance Sheets	Financial Instruments	Cash Collateral Received	Net Amount
Derivatives	$ 13,028	$ —	$ 13,028	$ —	$ —	$ 13,028

Offsetting of Derivative Assets (as of December 31, 2025)

				Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets		
(In thousands)	Gross Amounts of Recognized Assets	Gross Amounts Offset in the Condensed Consolidated Balance Sheet	Net Amounts of Assets in the Condensed Consolidated Balance Sheets	Financial Instruments	Cash Collateral Received	Net Amount
Derivatives	$ 6,691	$ —	$ 6,691	$ —	$ —	$ 6,691

Credit-risk-related Contingent Features

As of September 30, 2026, the Company had no derivatives in a net liability position. As of September 30, 2026, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.

NOTE 7. STOCKHOLDERS' EQUITY

Common Stock

The following table provides a reconciliation of the beginning and ending common stock balances for the nine months ended September 30, 2026 and for the year ended December 31, 2025:

(In thousands)	Nine Months Ended September 30, 2026	Year Ended December 31, 2025
Balance, beginning of period	28,471	28,242
Vested RSUs	22	28
Restricted stock issued, net of withheld shares and forfeitures	246	201
Balance, end of period	28,739	28,471

ATM Program

The Company has an at-the-market offering program ("ATM Program") with Piper Sandler & Co., Piper Sandler Financial Products II Inc., Evercore Group L.L.C., Fifth Third Securities, Inc., Huntington Securities, Inc., Janney Montgomery Scott LLC, KeyBanc Capital Markets Inc., Regions Securities LLC, Truist Bank, and Truist Securities, Inc. in their capacities as Sales Agents, Forward Purchasers and/or Forward Sellers (each, an “Agent”, and, collectively, the “Agents”).

Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $300.0 million, exclusive of shares of common stock sold under its prior agreements with our Agents. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the third amended and restated sales agency agreement and applicable law. In addition, the Company may enter into one or more forward sales agreements under the ATM Program.

The Company did not issue any shares under the ATM Program during the nine months ended September 30, 2026. As of September 30, 2026, the Company had $300.0 million remaining that may be issued under the ATM Program.

NOTE 8. NET INCOME (LOSS) PER COMMON SHARE

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and nine months ended September 30, 2026 and 2025, respectively. Net income (loss) available to common stockholders excludes dividends paid on participating securities which include restricted stock and time-based RSUs. Dividends accrue but are not paid on unvested performance-based RSUs.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(In thousands, except per share data)	**2026**	**2025**	**2026**	**2025**
Net income (loss)	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
Participating securities' share in earnings	(564)	(750)	(2,124)	(2,278)
Net income (loss), less participating securities' share in earnings	$ 2,504	$ 890	$ 5,856	$ (11,604)
Weighted average Common Shares outstanding				
Weighted average Common Shares outstanding	28,694	28,430	28,619	28,373
Unvested restricted shares	(1,624)	(1,496)	(1,593)	(1,549)
Weighted average Common Shares outstanding–Basic & Diluted	27,070	26,934	27,026	26,824
Net Income (Loss) Per Common Share - Basic & Diluted	$ 0.09	$ 0.03	$ 0.22	$ (0.43)

NOTE 9. STOCK INCENTIVE PLAN

Restricted Stock Awards

A summary of restricted stock award activity for the three and nine months ended September 30, 2026 and 2025 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable amortization periods.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(Dollars and shares in thousands)	**2026**	**2025**	**2026**	**2025**
Stock-based awards, beginning of period	1,608	1,455	1,518	1,560
Stock in lieu of compensation	60	64	143	153
Stock awards	39	44	142	158
Total stock granted	99	108	285	311
Vested shares	(57)	(43)	(152)	(349)
Forfeited shares	(3)	(2)	(4)	(4)
Stock-based awards, end of period	1,647	1,518	1,647	1,518
Amortization expense [1]	$ 1,594	$ 2,081	$ 6,212	$ 11,285

(1) Amortization expense for the nine months ended September 30, 2025 included accelerated amortization totaling $4.4 million related to the termination of a former executive officer.

Restricted Stock Issuances

During the first quarter of 2026, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted 101,305 shares of restricted common stock to its employees, in lieu of salary, that will cliff vest between three and eight years. Of the shares granted, 60,456 shares of restricted stock were granted in lieu of compensation from the program pool and 40,849 shares of restricted stock were awards granted from the plan pool. Also, during the first quarter of 2026, pursuant to the Second Amended and Restated Non-Executive Officer Incentive Program, the Company granted 18,103 shares of restricted stock to certain employees that will cliff vest in five years.

During the second quarter of 2026, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 66,165 shares of restricted stock to its Board

of Directors, in lieu of fees and compensation, which will cliff vest in three years. Of the shares granted, 21,908 shares of restricted stock were granted in lieu of compensation from the program pool and 44,257 shares of restricted stock were awarded based on the restriction period elected from the plan pool.

During the third quarter of 2026, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 99,145 shares of restricted stock to its employees, in lieu of bonus compensation, which will cliff vest between three and eight years. Of the shares granted, 60,796 shares of restricted stock were granted in lieu of compensation from the program pool and 38,349 shares of restricted stock were awarded based on the restriction period elected from the plan pool.

Restricted Stock Units

A summary of the Company's restricted stock unit (RSU) activity during the three and nine months ended September 30, 2026 and 2025, respectively, is included in the table below, as well as compensation expense recognized from the amortization of the value of RSUs over the applicable amortization periods.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(Dollars and RSUs in thousands)	**2026**	**2025**	**2026**	**2025**
Restricted Stock Units, beginning of period	97	95	205	123
Absolute TSR Performance-based RSUs granted [1]	29	36	29	36
Relative TSR Performance-based RSUs granted [1]	29	35	29	35
Time-based RSUs granted [2]	34	39	34	39
Total RSUs granted	92	110	92	110
Vested RSUs	—	—	(22)	(28)
Forfeited RSUs [3]	—	—	(86)	—
Restricted Stock Units, end of period	189	205	189	205
Amortization expense [4]	$ 309	$ 384	$ 1,180	$ 1,012

(1) The number of performance-based RSUs granted were based on target levels. These RSUs will vest or be forfeited based on the performance level achieved at the end of the respective three-year performance period on June 30, 2028 and 2029.

(2) The number of time-based RSUs granted were based on target levels and vest ratably on June 30 of each year of the respective three-year periods ending June 30, 2028 and 2029, provided the recipient remains continuously employed by the Company on each such date.

(3) RSUs with a three-year performance period ended June 30, 2026 did not meet required performance levels and were forfeited.

(4) Amortization expense of RSUs for the nine months ended September 30, 2025 includes accelerated amortization totaling $0.2 million related to the termination of a former executive officer.

Restricted Stock Unit Issuances

During the third quarter of 2026, pursuant to the 2024 Incentive Plan, the Company granted performance-based and time-based RSUs to its executive officers. These RSUs are forward-looking with a three-year performance period beginning July 1, 2026. The performance-based RSUs were valued by independent specialists utilizing a Monte Carlo simulation to calculate the grant date fair values of $19.04 per share for the Absolute TSR RSUs and $22.05 per share for the Relative TSR RSUs. The grant date value of the time-based RSUs was based on the Company's stock price on the grant date of $18.56.

NOTE 10. OTHER ASSETS, NET

Other assets, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 are detailed in the table below.

	Balance as of	
(Dollars in thousands)	**September 30, 2026**	**December 31, 2025**
Straight-line rent receivables, net	$ 24,275	$ 22,987
Fair value of interest rate swaps	13,028	6,691
Sales-type lessor receivables	7,708	7,894
Leasing commissions, net	6,943	5,253
Deferred financing costs, net	2,364	2,947
Financing lease right-of-use assets	2,324	2,368
Prepaid assets	2,004	1,547
Mortgage note receivable	2,000	2,000
Accounts and interest receivables, net	1,559	2,585
Notes receivable, net of credit loss reserve	1,380	1,830
Above-market intangible assets, net	995	1,307
Operating lease right of use assets	644	667
Other	881	1,163
Total other assets, net	$ 66,105	$ 59,239

The Company's notes and mortgage note receivable included the following at September 30, 2026 and December 31, 2025:

- At September 30, 2026 and December 31, 2025, notes receivable included a $17.0 million term loan and a $2.7 million revolving credit facility secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. The notes and interest receivables on these notes are fully reserved. At September 30, 2026, the Company had an unfunded commitment of $5.8 million on the revolving credit facility, however, any additional amounts requested by the borrower require Company management approval.

- At September 30, 2026 and December 31, 2025, notes receivable included a revolving credit facility with a borrower totaling $1.4 million and $1.8 million, respectively. The outstanding balance of the revolving credit facility will be repaid in monthly installments of $50,000 through the maturity date of April 1, 2027 with a balloon payment due at maturity. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note.

- At September 30, 2026 and December 31, 2025, the Company had a $2.0 million mortgage note receivable with a developer which is secured by the land, improvements, and personal property. The mortgage loan, which bears interest at 10% per annum, will be interest only until the principal is due at the earlier of the sale of the property, or August 15, 2027.

The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable.

The VIEs that we have identified at September 30, 2026 are summarized in the table below.

Classification	Carrying Amount *(in thousands)*	Maximum Exposure to Loss *(in thousands)*
Note receivable (revolving credit facility)	$ 1,380	$ 1,380
Note receivable (mortgage note)	$ 2,000	$ 2,000

NOTE 11. OTHER LIABILITIES, NET

Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 are detailed in the table below.

(Dollars in thousands)	Balance as of September 30, 2026	December 31, 2025
Prepaid rent	$ 5,476	$ 6,034
Security deposits	2,669	2,596
Below-market lease intangibles, net	1,149	1,583
Financing lease liability	3,234	3,246
Operating lease liability	739	750
Other	41	37
Total other liabilities, net	$ 13,308	$ 14,246

NOTE 12. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value.

Cash and cash equivalents - The carrying amount approximated the fair value. The fair value estimates were determined using level 1 inputs.

Notes and mortgage note receivable - The fair value was estimated using cash flow analyses which are based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and were classified as level 2 inputs in the hierarchy.

Notes receivable, net of credit loss - The fair value of these notes, net of credit loss, was estimated based on its estimated value of the underlying collateral on the notes and are classified as level 3 in the hierarchy.

Borrowings under our Credit Facility - The carrying amount approximated the fair value because the borrowings were based on variable market interest rates. The fair value estimates were determined using level 2 inputs.

Derivative financial instruments (Interest rate swaps) - The fair value was estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs were utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps were observable in active markets and were classified as level 2 inputs in the hierarchy.

The table below details the fair values and carrying values for our notes and mortgage note receivable, and interest rate swaps at September 30, 2026 and December 31, 2025.

	September 30, 2026		December 31, 2025	
(Dollars in thousands)	Carrying Value	Fair Value	Carrying Value	Fair Value
Notes and mortgage note receivable, level 2	$ 3,380	$ 3,410	$ 3,830	$ 3,964
Notes receivable, net of credit loss, level 3[1][2]	$ —	$ —	$ —	$ —
Interest rate swap asset	$ 13,028	$ 13,028	$ 6,691	$ 6,691

(1) These notes were fully reserved as of June 30, 2025 and the fair value measurement of these notes moved from utilizing Level 2 inputs to utilizing Level 3 inputs, based on its estimated value of the underlying collateral.

(2) Calculated utilizing Level 3 inputs at September 30, 2026 and December 31, 2025. See the table below for Level 3 activity for the nine months ended September 30, 2026 and the year ended December 31, 2025.

	Level 3 Inputs	
Notes Receivable:	September 30, 2026	December 31, 2025
Beginning fair value	$ —	$ 10,547
Payments	—	(1,875)
Credit loss reserve	—	(8,672)
Ending fair value	$ —	$ —

NOTE 13. COMMITMENTS AND CONTINGENCIES

Tenant Improvements

The Company may provide tenant improvement allowances in new or renewal leases for the purpose of refurbishing or renovating tenant space. The Company may also assume tenant improvement obligations included in leases acquired in its real estate acquisitions. As of September 30, 2026, the Company had approximately $28.7 million in commitments for tenant improvements, of which $1.7 million primarily relates to three redevelopment projects of buildings into different healthcare uses, backed by long-term leases.

Capital Improvements

The Company has entered into contracts with various vendors for various capital improvement projects related to its portfolio. As of September 30, 2026, the Company had approximately $4.4 million in commitments for capital improvement projects, of which $1.9 million primarily relates to three redevelopment projects of buildings into different healthcare uses, backed by long-term leases.

Legal Proceedings

The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's Consolidated Financial Statements.

NOTE 14. SUBSEQUENT EVENTS

Dividend Declared

On November 3, 2026, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.33 per share. The dividend is payable on November 25, 2026 to stockholders of record on November 13, 2026.

Dispositions

As part of the Company's capital recycling program, the Company sold two properties subsequent to September 30, 2026:

- On October 15, 2026, the Company sold an inpatient rehabilitation facility in Ohio for net proceeds of approximately $31.4 million. The property was included in assets held for sale at September 30, 2026. The proceeds from the sale are generally expected to fund acquisitions through like-kind exchange under

Section 1031 of the United States Internal Revenue Code. The Company expects to recognize a gain on sale of approximately $9.1 million.

- On October 1, 2026, the Company sold a vacant property in Alabama for net proceeds of approximately $0.2 million. In the third quarter of 2026, the Company recognized an impairment on this property that was classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.4 million, based on a contract to sell the property.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Disclosure Regarding Forward-Looking Statements

This report and other materials that Community Healthcare Trust Incorporated (the "Company") has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "believes", "expects", "may", "will", "should", "seeks", "approximately", "intends", "plans", "estimates", "anticipates" or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Thus, the Company's actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company's common stock, changes in the Company's business strategy, availability, terms and deployment of capital, the Company's ability to refinance existing indebtedness at or prior to maturity on favorable terms, or at all, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company's competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, changes in interest rates, supply chain disruptions, labor conditions, prolonged government shutdown or budgetary reductions or impasses, tariffs and global trade tensions, and/or conflicts in Ukraine and the Middle East, and other factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and the Company's other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this report and the Company undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.

The purpose of this Management's Discussion and Analysis ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash flows. MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Condensed Consolidated Financial Statements and accompanying notes.

Overview

References such as "we," "us," "our," and "the Company" mean Community Healthcare Trust Incorporated, a Maryland corporation, and its consolidated subsidiaries.

We were organized in the State of Maryland on March 28, 2014. We are a self-administered, self-managed healthcare real estate investment trust, or REIT, that acquires and owns properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers.

Trends and Matters Impacting Operating Results

Management monitors factors and trends that it believes are important to the Company and the REIT industry in order to gauge their potential impact on the operations of the Company. Certain of the factors and trends that management believes may impact the operations of the Company are discussed below.

Asset Acquisitions

During the first quarter of 2026, the Company acquired one inpatient rehabilitation facility totaling approximately 37,151 square feet for an aggregate purchase price and cash consideration of approximately $28.5 million. The property was 100.0% leased with a lease expiration in 2044. Amounts reflected in revenues and net income for the property for the nine months ended September 30, 2026 were approximately $1.9 million and $1.6 million, respectively. The acquisition was funded with net proceeds from the Company's Revolving Credit Facility and from asset sales. See Note 4 – Real Estate Acquisition, Disposition, and Assets Held for Sale to the Condensed Consolidated Financial Statements for more details on this acquisition.

Acquisition Pipeline

The Company has four properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $99.0 million. The Company anticipates closing on the first of these properties in the fourth quarter of 2026, a second in the first quarter of 2027, and the remaining two between mid-2027 and early 2028; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions with cash from operations, with net proceeds from equity or debt issuances, with the Company's Revolving Credit Facility, or from asset sales.

Asset Dispositions

During the nine months ended September 30, 2026, the Company sold three properties, received aggregate net proceeds of approximately $5.7 million, and recorded a $0.7 million loss on sale in the aggregate. During the first quarter of 2026, the Company also received net cash proceeds of approximately $0.7 million for a property disposed of during the fourth quarter of 2025. The net proceeds were used to repay outstanding balances on the Company's Revolving Credit Facility.

Subsequent to September 30, 2026, the Company sold two properties as part of the Company's capital recycling program for net proceeds totaling approximately $31.5 million. The proceeds are expected to fund acquisitions through like-kind exchange under Section 1031 and to be used for general corporate purposes. The Company recognized an impairment of $0.4 million during the third quarter related to the sale of one property and expects to recognize a gain in the fourth quarter of approximately $9.1 million on the sale of the other property. See Note 14 – Subsequent Events for more details.

Leased Square Footage

As of September 30, 2026, our real estate portfolio, excluding assets held for sale, was approximately 90.1% leased. During the first nine months of 2026, we had expiring or terminated leases related to approximately 493,000 square feet, and we leased or renewed leases relating to approximately 450,000 square feet.

Interest Expense

On March 29, 2026, the Company's interest rate swaps that had fixed the interest rate at a weighted average rate of approximately 3.8% on $75.0 million of its Revolving Credit Facility balance matured. The Company has not replaced these interest rate swaps, so interest on the $75.0 million is now under the Revolving Credit Facility floating rate. The floating rate for the Revolving Credit Facility at September 30, 2026 was approximately 5.6%. See Note 5 – Debt, net for more details on the Company's debt.

Inflation

Inflation has significantly increased during the past several years and a prolonged period of high and persistent inflation could cause an increase in our expenses, capital expenditures, and cost of our variable-rate borrowings which could have a material impact on our financial position or results of operations. Many of our lease agreements contain provisions designed to mitigate the adverse impact of inflation, including annual rent increases based on stated increases or CPI increases. In response to inflationary pressures, the Federal Reserve raised interest rates in 2022 and 2023, however, the Federal Reserve lowered interest rates in 2024 and 2025, but have raised interest rates

during 2026 and may provide additional rate increases during the remainder of 2026. Higher interest rates may adversely impact real estate asset values and increase our interest expense on our variable-rate borrowings under our revolving credit facility.

Results of Operations

The Company's results of operations for the three and nine months ended September 30, 2026 compared to the same periods in 2025 were impacted by real estate acquisitions and dispositions, and interest expense, as well as other items discussed in more detail below.

Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025

Revenues

Rental income increased approximately $1.4 million, or 4.5%, for the three months ended September 30, 2026 compared to the same period in 2025 due mainly to the following:

- Acquisitions of real estate properties during 2025 and 2026 resulted in an increase in rental income of approximately $1.7 million in 2026 compared to 2025;
- Cash collections for the geriatric behavioral tenant in six of our properties placed on cash basis in 2025 resulted in an increase of $0.3 million; offset partially by
- A decrease in rental income of approximately $0.2 million related to a tenant placed on cash basis during the three months ended June 30, 2026;
- Real estate properties sold during 2025 and 2026 resulted in a decrease in rental income of approximately $0.7 million in 2026 compared to 2025; and
- The remaining $0.3 million increase resulted mainly from net leasing activities.

Expenses

Property operating expenses remained fairly flat at $6.0 million and $5.9 million, respectively, for the three months ended September 30, 2026 compared to 2025 and there were no material variances within the various expenses within property operating expenses.

General and administrative expenses decreased approximately $0.5 million, or 10.0%, for the three months ended September 30, 2026 compared to the same period in 2025 due mainly to a reduction in the non-cash amortization of stock-based compensation primarily due to fully amortized restricted stock shares and units.

Depreciation and amortization expense decreased by approximately $0.2 million, or 2.1%, for the three months ended September 30, 2026 compared to the same period in 2025 due mainly to the following:

- Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $0.8 million;
- Real estate properties sold during 2026 and 2025 resulted in a decrease of approximately $0.1 million; offset partially by
- Acquisition of real estate properties during 2026 and 2025 resulted in an increase of approximately $0.3 million; and
- Tenant and other capital expenditures resulted in an increase of approximately $0.4 million.

Losses on sale and impairment of real estate assets, net of gains on sale

Losses on sale and impairment of real estate assets, net of gains on sale increased by approximately $0.2 million, or 17.0% for the three months ended September 30, 2026 compared to the same period in 2025. This increase was due mainly to the following:

- During the three months ended September 30, 2026, the Company sold a property in Illinois and recognized a loss on sale of the real estate totaling approximately $0.7 million. Also during the three months ended September 30, 2026, the Company recorded an impairment on a property classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.4 million, based on a contract to sell the property.

- During the three months ended September 30, 2025, the Company sold a property in Pennsylvania and recognized a loss on sale of the real estate totaling approximately $0.2 million. Also during the three months ended September 30, 2025, the Company recorded an impairment on a property classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.7 million, based on a contract to sell the property.

Interest expense

Interest expense increased approximately $0.4 million, or 6.2%, for the three months ended September 30, 2026 compared to the same period in 2025 due mainly to an increase in the weighted average balance on the Revolving Credit Facility and the maturity of three interest rate swaps on $75 million of the Revolving Credit Facility in March 2026, which were not replaced.

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

Revenues

Rental income increased approximately $3.8 million, or 4.1%, for the nine months ended September 30, 2026 compared to the same period in 2025 due mainly to the following:

- Acquisitions of real estate properties during 2025 and 2026 resulted in an increase in rental income of approximately $6.2 million in 2026 compared to 2025;

- Cash collections for the geriatric behavioral tenant in six of our properties placed on cash basis in 2025 resulted in an increase of $0.7 million; offset partially by

- A decrease in rental income of approximately $0.5 million and non-cash straight line rent of approximately $0.6 million related to a tenant placed on cash basis during the three months ended June 30, 2026;

- Real estate properties sold during 2025 and 2026 resulted in a decrease in rental income of approximately $2.1 million; and

- The remaining $0.1 million net increase resulted from various other items, including leasing activities.

Other operating interest increased $1.2 million for the nine months ended September 30, 2026 compared to the same period in 2025 due mainly to the following:

- During the nine months ended September 30, 2025, the Company reversed interest receivables due from geriatric behavioral hospital tenant totaling approximately $1.5 million; offset partially by

- Interest income recognized in 2025 totaling approximately $0.3 million related to a loan that was repaid in June 2025.

Expenses

Property operating expenses increased approximately $0.6 million, or 3.4%, for the nine months ended September 30, 2026 compared to the same period in 2025, due mainly to:

- Property operating expenses increased approximately $0.3 million due to leasing commissions, $0.2 million due to real estate taxes, $0.2 million due to utilities, $0.1 million due to repairs and maintenance costs, $0.1 million due to landscaping costs (including snow plow); offset partially by
- A reduction of approximately $0.3 million in expenses due to real estate properties sold during 2025 and 2026.

General and administrative expenses decreased approximately $6.1 million, or 30.2%, for the nine months ended September 30, 2026 compared to the same period in 2025 due mainly to:

- During the second quarter of 2025, upon termination of a former executive officer, in accordance with the terms of his employment agreement, the Company accelerated the unamortized remaining balance of deferred compensation and recognized approximately $4.6 million of non-cash amortization expense. Additionally, the Company recognized approximately $1.3 million of severance and transition-related expenses; and
- Non-cash amortization of other stock-based compensation decreased approximately $0.3 million for the nine months ended September 30, 2026 compared to the same period in 2025 primarily due to fully amortized restricted stock shares and units.

Depreciation and amortization expense decreased approximately $0.7 million, or 2.0%, for the nine months ended September 30, 2026 compared to the same period in 2025. This decrease was comprised mainly of the following:

- Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $2.2 million; and
- Real estate properties sold during 2025 and 2026 resulted in a decrease of approximately $0.5 million; offset partially by
- Acquisitions of real estate properties in 2025 and 2026 resulted in an increase of approximately $1.1 million; and
- Tenant improvements and other capital expenditures resulted in an increase of approximately $0.9 million.

Losses on sale and impairment of real estate assets, net of gains on sale

Losses on sale and impairment of real estate assets, net of gains on sale increased by approximately $0.8 million for the nine months ended September 30, 2026 compared to the same period in 2025.

During the nine months ended September 30, 2026, the Company recognized a loss on sale and impairment, net of gains on sale of approximately $1.0 million due mainly to the following:

- A loss on the sale of a real estate property in Illinois totaling approximately $0.7 million; and
- An impairment on a property in Alabama classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.4 million, based on a contract to sell the property.

During the nine months ended September 30, 2025, the Company recognized a loss on sale and impairment, net of gains on sale of approximately $0.2 million, due mainly to the following:

- A loss on the sale of a real estate property in Pennsylvania totaling approximately $0.2 million.
- An impairment on a property in Florida classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.9 million, based on a contract to sell the property.
- An impairment on a property in Rhode Island classified as held for sale at the lower of the net book value and fair value less estimated cost to sell of approximately $0.7 million, based on a contract to sell the property.
- The Company amended an expired lease with a tenant which converted it from an operating lease to a sales-type lease. The Company recognized a gain on sale of the real estate totaling approximately $1.3 million.
- The Company sold a property in Ohio and recognized a gain on the sale of approximately $0.2 million.

Interest expense

Interest expense increased approximately $1.7 million, or 8.6%, for the nine months ended September 30, 2026 compared to the same period in 2025 due mainly to an increase in the weighted average balance on the Revolving Credit Facility and the maturity of three interest rate swaps on $75 million of the Revolving Credit Facility in March 2026, which were not replaced.

Credit loss reserve

A credit loss reserve totaling $8.7 million was recorded in 2025 related to notes receivable with a geriatric inpatient behavioral hospital tenant, fully reserving these notes in 2025. See Note 10 – Other Assets, net for more details.

Non-GAAP Financial Measures and Key Performance Indicators

Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO") and Adjusted Funds from Operations ("AFFO")

FFO is an operating performance measure adopted by the National Association of Real Estate Investment Trusts, Inc. ("NAREIT"). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT's operating performance equal to net income (calculated in accordance with GAAP), excluding gains or losses from the sale of certain real estate assets, gains and losses from change in control, impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity, plus depreciation and amortization related to real estate properties, and after adjustments for unconsolidated partnerships and joint ventures. NAREIT also provides REITs with an option to exclude gains, losses and impairments of assets that are incidental to the main business of the REIT from the calculation of FFO.

In addition to FFO, the Company presents AFFO and AFFO per share. The Company defines AFFO as FFO, excluding certain expenses related to closing costs of properties acquired accounted for as business combinations and mortgages funded, excluding straight-line rent and the amortization of stock-based compensation, and including or excluding other non-cash items from time to time. AFFO presented herein may not be comparable to similar measures presented by other real estate companies due to the fact that not all real estate companies use the same definition.

Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO, AFFO, FFO per share and AFFO per share provide an understanding of the operating performance of the Company's properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, losses and impairment of incidental assets, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO, AFFO, FFO per share and AFFO per share can facilitate comparisons of operating performance between periods. The table below reconciles net income (loss) to FFO and AFFO for the three and nine months ended September 30, 2026 compared to the same periods in 2025.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(In thousands, except per share amounts)	**2026**	**2025**	**2026**	**2025**
Net income (loss)	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
Real estate depreciation and amortization	10,853	11,019	32,558	32,957
Losses on sale and impairment of real estate assets, net of gains on sale	1,039	888	1,039	248
Credit loss reserve [1]	—	—	—	8,672
FFO	14,960	13,547	41,577	32,551
Straight-line rent	(846)	(913)	(2,197)	(2,736)
Stock-based compensation	1,903	2,465	7,392	7,706
Accelerated amortization of deferred compensation [2]	—	—	—	4,591
Severance and transition related expenses [2]	—	—	—	1,311
AFFO	$ 16,017	$ 15,099	$ 46,772	$ 43,423
FFO per diluted common share [1][2][3]	$ 0.54	$ 0.50	$ 1.50	$ 1.20
AFFO per diluted common share [1][2][3]	$ 0.58	$ 0.56	$ 1.69	$ 1.60
Weighted average common shares outstanding - diluted [4]	27,744	27,195	27,656	27,070

[1] During the nine months ended September 30, 2025, the Company recorded a credit loss reserve on its notes related to a geriatric behavioral hospital tenant totaling approximately $8.7 million. Because these notes are incidental to the Company's main business, the Company added back these reserves in its calculations of FFO and AFFO.

(2) During the nine months ended September 30, 2025, the Company recorded severance and transition-related charges totaling approximately $5.9 million, including non-cash accelerated amortization of stock-based compensation of approximately $4.6 million, which in total reduced FFO per diluted common share by approximately $0.22 for the nine months ended September 30, 2025.

(3) During the nine months ended September 30, 2025, the Company reversed interest related to a geriatric behavioral hospital tenant totaling approximately $1.7 million, resulting in a reduction of FFO and AFFO per diluted share of approximately $0.06.

(4) Diluted weighted average common shares outstanding for FFO and AFFO are calculated based on the treasury method, rather than the 2-class method used to calculate earnings per share. Restricted stock awards and time-based RSUs are included in the calculation of weighted average common shares outstanding to the extent that they are dilutive. Performance-based RSUs are included in the calculation of weighted average common shares outstanding to the extent that they are in-the-money as of the end of the reporting period and are dilutive.

Net Operating Income ("NOI")

NOI is a key performance indicator. NOI is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, gains or loss on the sale of real estate properties or other investments, interest expense, and income tax expense. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. The Company's use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing NOI.

The table below reconciles net income (loss) to NOI for the three and nine months ended September 30, 2026 compared to the same periods in 2025.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(In thousands)	**2026**	**2025**	**2026**	**2025**
Net income (loss)[1]	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
General and administrative	4,191	4,658	14,189	14,415
Severance and transition-related compensation [2]	—	—	—	5,902
Depreciation and amortization	10,668	10,902	32,063	32,724
Losses on sale and impairment of real estate assets, net of gains on sale	1,039	888	1,039	248
Credit loss reserve [3]	—	—	—	8,672
Interest expense	7,515	7,075	21,742	20,019
Deferred income tax benefit	—	—	(12)	—
Interest and other income, net	(13)	(7)	(19)	(15)
NOI	$ 26,468	$ 25,156	$ 76,982	$ 72,639

(1) During the nine months ended September 30, 2025, the Company reversed interest totaling approximately $1.7 million relating to a geriatric behavioral hospital tenant.

(2) Severance and transition-related compensation, which is included in general and administrative expenses on the income statement, is shown separately in the reconciliation above for the nine months ended September 30, 2025.

(3) During the nine months ended September 30, 2025, the Company recorded a credit loss reserve on its notes related to a geriatric behavioral hospital tenant totaling approximately $8.7 million.

EBITDA*re* and Adjusted EBITDA*re*

The Company uses the NAREIT definition of EBITDA*re* which is net income or loss plus interest expense, income tax expense, and depreciation and amortization, plus losses or minus gains on the disposition of depreciable property, including losses/gains on change of control, plus impairment write-downs of depreciable property and of investments in unconsolidated affiliates caused by a decrease in value of depreciable property in the affiliate, plus or minus adjustments to reflect the entity's share of EBITDA*re* of unconsolidated affiliates and consolidated affiliates with non-controlling interest. The Company also presents Adjusted EBITDA*re* which is EBITDA*re* before non-cash stock-based compensation expense, accelerated amortization of deferred compensation, and credit loss reserve.

We consider EBITDA*re* and Adjusted EBITDA*re* important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

The table below reconciles net income (loss) to EBITDA*re* and Adjusted EBITDA*re* for the three and nine months ended September 30, 2026 compared to the same periods in 2025.

	Three Months Ended September 30,		Nine Months Ended September 30,	
(In thousands)	**2026**	**2025**	**2026**	**2025**
Net income (loss)[1][2]	$ 3,068	$ 1,640	$ 7,980	$ (9,326)
Interest expense	7,515	7,075	21,742	20,019
Depreciation and amortization	10,668	10,902	32,063	32,724
Deferred income tax benefit	—	—	(12)	—
Losses on sale and impairment of real estate assets, net of gains on sale	1,039	888	1,039	248
EBITDA*re*	$ 22,290	$ 20,505	$ 62,812	$ 43,665
Non-cash stock-based compensation expense	1,903	2,465	7,392	7,706
Accelerated amortization of deferred compensation	—	—	—	4,591
Credit loss reserve	—	—	—	8,672
Adjusted EBITDA*re*	$ 24,193	$ 22,970	$ 70,204	$ 64,634

[1] During the nine months ended September 30, 2025, the Company reversed interest totaling approximately $1.7 million for a geriatric behavioral hospital tenant.
[2] During the nine months ended September 30, 2025, the Company recognized severance and transition-related charges totaling approximately $1.3 million.

Liquidity and Capital Resources

The Company monitors its liquidity and capital resources and relies on several key indicators in its assessment of capital markets for financing acquisitions and other operating activities as needed, including the following:

- Leverage ratios and financial covenants included in our Credit Facility;
- Dividend payout percentage; and
- Interest rates, underlying treasury rates, debt market spreads and equity markets.

The Company uses these indicators and others to compare its operations to its peers and to help identify areas in which the Company may need to focus its attention.

Sources and Uses of Cash

The Company derives most of its revenues from its real estate properties, collecting rental income and operating expense reimbursements based on contractual arrangements with its tenants. These sources of revenue represent our primary source of liquidity to fund our dividends, general and administrative expenses, property operating expenses, interest expense on our Credit Facility and other expenses incurred related to managing our existing portfolio and investing in existing or in additional properties. To the extent additional resources are needed, the Company will fund its investment activity generally with net proceeds from equity or debt issuances, including our at-the-market equity offering program, either in the public or private markets, from our Credit Facility, or from asset sales.

The Company expects to meet its liquidity needs through cash on hand, cash flows from operations and cash flows from sources discussed above. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Operating Activities

Cash flows provided by operating activities for the nine months ended September 30, 2026 and 2025 were approximately $45.1 million and $40.9 million, respectively. Cash flows provided by operating activities were generally provided by contractual rents, net of property operating expenses not reimbursed by the tenants, general and administrative expenses, and interest expense paid on our Credit Facility.

Investing Activities

Cash flows used in investing activities for the nine months ended September 30, 2026 and 2025 were approximately $35.6 million and $43.7 million, respectively. During the nine months ended September 30, 2026, the Company acquired one property for cash consideration of approximately $28.5 million, received cash consideration totaling approximately $6.4 million on dispositions, received payments on its notes totaling $0.5 million and funded capital expenditures and tenant improvements on its existing portfolio totaling approximately $13.9 million.

During the nine months ended September 30, 2025, the Company invested in two properties for an aggregate cash consideration of approximately $36.1 million, received cash consideration totaling approximately $1.3 million on dispositions, received payments on its notes receivable totaling $5.1 million and funded capital expenditures and tenant improvements on its existing portfolio totaling approximately $14.0 million.

Financing Activities

Cash flows used in financing activities for the nine months ended September 30, 2026 were approximately $11.6 million and cash flows provided by financing activities for the nine months ended September 30, 2025 were approximately $1.8 million. During the nine months ended September 30, 2026, the Company borrowed $26.0 million under its Revolving Credit Facility and paid dividends totaling approximately $36.9 million. Also, upon the vesting of stock-based awards for certain employees, the Company withheld shares and paid taxes totaling approximately $0.6 million on behalf of employees.

During the nine months ended September 30, 2025, the Company borrowed a net amount of $44.0 million under its Revolving Credit Facility and paid dividends totaling approximately $40.1 million. Also, upon the vesting of stock-based awards for certain employees, the Company withheld shares and paid taxes totaling approximately $1.8 million on behalf of employees.

Acquisition Pipeline

The Company has four properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $99.0 million. The Company anticipates closing on the first of these properties in the fourth quarter of 2026, a second in the first quarter of 2027, and the remaining two between mid-2027 and early 2028; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions with cash from operations, with net proceeds from equity or debt issuances, with the Company's Revolving Credit Facility, or from asset sales.

Tenant Improvements and Capital Improvements

Subject to Company approval, we may fund or reimburse tenants for tenant improvements, which are allowed for in certain leases, of up to approximately $28.7 million as of September 30, 2026. At September 30, 2026, $1.7 million of this commitment relates primarily to three redevelopment projects on buildings with tenants backed by long-term leases.

The Company has also entered into contracts regarding certain capital expenditures with remaining commitments totaling approximately $4.4 million as of September 30, 2026. At September 30, 2026, $1.9 million of this commitment relates primarily to three redevelopment projects of buildings into different healthcare uses backed by long-term leases.

The Company expects to fund these expenditures with cash from operations, with net proceeds from equity or debt issuances, from our Credit Facility, or from asset sales.

Subsequent Dispositions

Subsequent to September 30, 2026, the Company sold two properties as part of the Company's capital recycling program for net proceeds totaling approximately $31.5 million. The proceeds are expected to fund acquisitions through like-kind exchange under Section 1031 and to be used for general corporate purposes. See Note 14 – Subsequent Events for more details.

Credit Facility

At September 30, 2026, the Company had $284.0 million outstanding on its Revolving Credit Facility with a maturity on October 16, 2029. In addition, the Company has $275.0 million outstanding in Term Loans with expirations beginning in 2028 through 2030. The Company has entered into interest rate swaps to fix the interest rates on $275.0 million of the Term Loans, with maturities matching the maturity dates of the notes. See Note 5 – Debt, net to the Condensed Consolidated Financial Statements which provides more details on the Company's Credit Facility. At September 30, 2026, the Company had borrowing capacity remaining under the Revolving Credit Facility of approximately $116.0 million.

The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2026.

Ground Leases

At September 30, 2026, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. At September 30, 2026, the Company's aggregate obligation under these ground leases was approximately $8.4 million, of which approximately $50 thousand is due during the remainder of 2026 and $0.2 million is due in 2027. See Note 3 – Real Estate Leases to the Condensed Consolidated Financial Statements.

Notes Receivable

The Company has a note with a tenant with unfunded commitments remaining totaling $5.8 million at September 30, 2026. Any future requests for borrowings under the revolving credit facility from this tenant, however, would require approval by the Company's management. See Note 10 – Other Assets, net to the Condensed Consolidated Financial Statements.

Universal Shelf Registration Statement

On February 19, 2025, the Company filed a new non-automatic shelf registration statement on Form S-3 with the Securities and Exchange Commission which became effective on March 14, 2025. The registration statement is for $500.0 million of securities and is effective for three years. Under this registration statement, the Company has the capacity to offer and sell from time to time various types of securities, including common stock, preferred stock, depository shares, rights, debt securities, warrants and units.

ATM Program

Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $300.0 million, exclusive of shares of common stock sold under its prior agreements with our Agents. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the third amended and restated sales agency agreement and applicable law. In addition, the Company may enter into one or more forward sales agreements under the ATM Program. As of September 30, 2026, the Company had $300.0 million remaining that may be issued under the ATM Program.

Security Deposits

As of September 30, 2026, the Company held approximately $2.7 million in security deposits for the benefit of the Company in the event the obligated tenant fails to perform under the terms of its respective lease. Generally, the Company may, at its discretion and upon notification to the tenant, draw upon the security deposits if there are any defaults under the leases.

Dividends

The Company is required to pay dividends to its stockholders at least equal to 90% of its taxable income in order to maintain its qualification as a REIT.

On November 3, 2026, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.33 per share. The dividend is payable on November 25, 2026 to stockholders of record on November 13, 2026. This rate equates to an annualized dividend of $1.32 per share.

The ability of the Company to pay dividends is dependent upon its ability to generate cash flows and to make accretive new investments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We may use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We will not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. An interest rate swap is a contractual agreement entered into by two counterparties under which each agrees to make periodic payments to the other for an agreed period of time based on a notional amount of principal. Under the most common form of interest rate swap, known from our perspective as a floating-to-fixed interest rate swap, a series of floating, or variable, rate payments on a notional amount of principal is exchanged for a series of fixed interest rate payments on such notional amount. During the nine months ended September 30, 2026, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, other than the expiration of the $75.0 million of interest rate swaps in the first quarter of 2026 as discussed in Note 5 – Debt, net to the Condensed Consolidated Financial Statements.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, the Company's disclosure controls and procedures were effective.

Changes In Internal Control Over Financial Reporting

There were no changes in our system of internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in our Quarterly Reports on Form 10-Q for the current year, an investor should consider the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2025 and other reports that may be filed by the Company. There were no material changes in the risk factors presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended September 30, 2026, the Company canceled shares of the Company's common stock to satisfy employee tax withholding obligations upon the vesting of stock-based awards, as follows:

Period	Total Number of Shares Purchased	Average Price Paid per share	Total Number of Shares purchased as part of publicly announced plans or programs	Maximum Number of Shares that may yet be purchased under the plans or programs
July 1 - July 31	—	$ —	—	—
August 1 - August 31	12,180	$ 16.16	—	—
September 1 - September 30	—	$ —	—	—
Total	12,180			

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

Rule 10b5-1

During the quarter ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

ITEM 6. EXHIBITS

The exhibits required by Item 601 of Regulation S-K which are filed with this report are listed in the Exhibit Index and are hereby incorporated in by reference.

EXHIBIT INDEX

Exhibit No.	Description
3.1	Corporate Charter of Community Healthcare Trust Incorporated, as amended (1)
3.2	Amended and Restated Bylaws of Community Healthcare Trust Incorporated (2)
10.1 *	Amendment No. 1 to the Second Amended and Restated Non-Executive Officer Incentive Program
31.1 *	Certification of the Chief Executive Officer of Community Healthcare Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 *	Certification of the Chief Financial Officer of Community Healthcare Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 **	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

(1) Filed as Exhibit 3.1 to Amendment No. 2 to the Registration Statement on Form S-11 of the Company filed with the Securities and Exchange Commission on May 6, 2015 (Registration No. 333-203210) and incorporated herein by reference.
(2) Filed as Exhibit 3.2 to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 3, 2020 (File No. 001-37401) and incorporated herein by reference.

* Filed herewith.
** Furnished herewith.
† Denotes executive compensation plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 3, 2026

COMMUNITY HEALTHCARE TRUST INCORPORATED

By: /s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President

By: /s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and Chief Financial Officer